The Hyderabad-based bio-pharmaceutical company, Celestial Biolabs Ltd has announced that it is set to launch its latest anti-diabetic product, which is expected to be a breakthrough in research and in the management of diabetes.
Through in-house research on the anti-diabetic activities of macro algal bio-active compounds in streptozotocin induced diabetic models, the product was shown to be safe from acute and chronic toxicity on experimental subjects. The company is in the process of launching this natural sea based 100% vegetarian product tentatively by April 2015.
Celestial Biolabs, which is engaged in manufacturing of bio-pharmaceutical products, had earlier lunched patented arthritis management product, Cadalmin GAe.
Through in-house research on the anti-diabetic activities of macro algal bio-active compounds in streptozotocin induced diabetic models, the product was shown to be safe from acute and chronic toxicity on experimental subjects. The company is in the process of launching this natural sea based 100% vegetarian product tentatively by April 2015.
Celestial Biolabs, which is engaged in manufacturing of bio-pharmaceutical products, had earlier lunched patented arthritis management product, Cadalmin GAe.